FOLH1 and neoplasm: Immunotherapy has made remarkable progressas a therapeutic strategytargeting PSMA-positive PCa, primarily focused on T-cell-directedcytotoxicity.19,36,43−48 Despite these advancements, immunotherapy of PCa is still in earlydevelopmental stages, mostly due to the significant challenges posedby the heterogeneity of the tumor microenvironment.